|
|
Article: Trimeris, Roche Increase Capacity For Fuzeon, Release More Data.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Reports of increased global supplies of Fuzeon, coupled with longer-term data on the product, gave Trimeris Inc. a boost from investors eyeing higher earnings from early sales of the FDA-approved HIV drug.
Shares in the Durham, N.C.-based firm (NASDAQ:TRMS) gained 99 percent Tuesday, a $4.93 climb, to close at $54.54 as the news came out at the International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris.
While clinical data supported prior findings of Fuzeon's ability to improve immune responses, Trimeris and development partner F. Hoffmann-La Roche Ltd. turned heads with news of increased quantities of the ...